Compounds > 6-ketoprostaglandin-f1-alpha

6-ketoprostaglandin-f1-alpha and Graves-Disease

6-ketoprostaglandin-f1-alpha has been researched along with Graves-Disease* in 2 studies

Other Studies

2 other study(ies) available for 6-ketoprostaglandin-f1-alpha and Graves-Disease

Article	Year
Circulating prostacyclin and thromboxane in patients with Graves' disease. Prostaglandins, leukotrienes, and medicine, 1987, Volume: 26, Issue:1 We measured plasma levels of PGI2 as 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) and thromboxane A2 (TXA2) as thromboxane B2 (TXB2) in patients with Graves' disease and in normal subjects. The levels of plasma 6-keto-PGF1 alpha were significantly elevated and correlated with those of serum T4 and T3, respectively, in hyperthyroid patients with Graves' disease. Significant reduction of 6-keto-PGF1 alpha levels was observed after antithyroid drug therapy. In contrast, the levels of plasma TXB2 were significantly lower in untreated patients with Graves' disease than in normal subjects. These data suggest that an elevation of plasma 6-keto-PGF1 alpha may play some additional role in pathophysiology of Graves' disease. Topics: 6-Ketoprostaglandin F1 alpha; Adolescent; Adult; Epoprostenol; Graves Disease; Humans; Middle Aged; Thromboxane A2; Thromboxanes; Thyroid Hormones	1987
Differences in prostaglandin E2, prostaglandin F2 alpha and prostacyclin contents and their response to thyrotrophin stimulation and in prostaglandin-stimulated cyclic AMP response in normal and Grave's thyroid slices. The Journal of endocrinology, 1983, Volume: 98, Issue:3 The human thyroid contained prostaglandin (PG) E2, PGF2 alpha and 6-oxo-PGF1 alpha, an end-metabolite of prostacyclin (PGI2), the 6-oxo-PGF1 alpha content being the highest of these prostaglandins. Graves's thyroid contained a significantly higher amount of PGF2 alpha and lower amounts of PGE2 and 6-oxo-PGF1 alpha than the normal thyroid. Thyrotrophin acutely augmented the thyroid contents of PGE2, PGF2 alpha and 6-oxo-PGF1 alpha. The TSH-stimulated increases in PGE2 and 6-oxo-PGF1 alpha were lower but the TSH-stimulated increase in PGF2 alpha was significantly higher in Graves's thyroid than in the normal thyroid. Prostaglandin E2 and PGI2 stimulated human thyroid cyclic AMP synthesis, with the magnitudes of PGE2- and PGI2-stimulated increases in cyclic AMP being equal in normal and Graves's thyroid. Prostaglandin F2 alpha did not stimulate cyclic AMP synthesis significantly. These results provide evidence that prostaglandins play important roles in thyroid physiology and the pathophysiology of Graves's disease. Topics: 6-Ketoprostaglandin F1 alpha; Cyclic AMP; Dinoprost; Dinoprostone; Epoprostenol; Graves Disease; Humans; In Vitro Techniques; Prostaglandins E; Prostaglandins F; Thyroid Gland; Thyrotropin	1983

Article

Year

Circulating prostacyclin and thromboxane in patients with Graves' disease.

Prostaglandins, leukotrienes, and medicine, 1987, Volume: 26, Issue:1

We measured plasma levels of PGI2 as 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) and thromboxane A2 (TXA2) as thromboxane B2 (TXB2) in patients with Graves' disease and in normal subjects. The levels of plasma 6-keto-PGF1 alpha were significantly elevated and correlated with those of serum T4 and T3, respectively, in hyperthyroid patients with Graves' disease. Significant reduction of 6-keto-PGF1 alpha levels was observed after antithyroid drug therapy. In contrast, the levels of plasma TXB2 were significantly lower in untreated patients with Graves' disease than in normal subjects. These data suggest that an elevation of plasma 6-keto-PGF1 alpha may play some additional role in pathophysiology of Graves' disease.

Topics: 6-Ketoprostaglandin F1 alpha; Adolescent; Adult; Epoprostenol; Graves Disease; Humans; Middle Aged; Thromboxane A2; Thromboxanes; Thyroid Hormones

1987

Differences in prostaglandin E2, prostaglandin F2 alpha and prostacyclin contents and their response to thyrotrophin stimulation and in prostaglandin-stimulated cyclic AMP response in normal and Grave's thyroid slices.

The Journal of endocrinology, 1983, Volume: 98, Issue:3

The human thyroid contained prostaglandin (PG) E2, PGF2 alpha and 6-oxo-PGF1 alpha, an end-metabolite of prostacyclin (PGI2), the 6-oxo-PGF1 alpha content being the highest of these prostaglandins. Graves's thyroid contained a significantly higher amount of PGF2 alpha and lower amounts of PGE2 and 6-oxo-PGF1 alpha than the normal thyroid. Thyrotrophin acutely augmented the thyroid contents of PGE2, PGF2 alpha and 6-oxo-PGF1 alpha. The TSH-stimulated increases in PGE2 and 6-oxo-PGF1 alpha were lower but the TSH-stimulated increase in PGF2 alpha was significantly higher in Graves's thyroid than in the normal thyroid. Prostaglandin E2 and PGI2 stimulated human thyroid cyclic AMP synthesis, with the magnitudes of PGE2- and PGI2-stimulated increases in cyclic AMP being equal in normal and Graves's thyroid. Prostaglandin F2 alpha did not stimulate cyclic AMP synthesis significantly. These results provide evidence that prostaglandins play important roles in thyroid physiology and the pathophysiology of Graves's disease.

Topics: 6-Ketoprostaglandin F1 alpha; Cyclic AMP; Dinoprost; Dinoprostone; Epoprostenol; Graves Disease; Humans; In Vitro Techniques; Prostaglandins E; Prostaglandins F; Thyroid Gland; Thyrotropin

1983